Neovici Holding AB (publ) (IDLDX) fair value: what the stock is really worth
As of Oct 13, 2026: fair value of Neovici Holding AB (publ) SEK 0.12, price SEK 0.35, upside -65.7%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever.
Show more
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Stock analysis
Neovici Holding AB (publ) (IDLDX) currently trades at kr 0.3500, while our model-based Fair Value estimate is kr 0.1200, 65.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: kr 0.0800 (bear) to kr 0.1500 (bull), the price of kr 0.3500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Neovici Holding AB (publ) reported revenue of 53.1M SEK in FY2025 versus 12.0M SEK in FY2021, a compound +45.1%/yr. Reported net income was −12.2M SEK in FY2025.
Key figures
Market cap 80.6M SEK (≈ $8.1M) · P/S ratio 1.45 · EPS (TTM) kr −0.0200 · Net margin −22.9% · Return on equity −3.6% · Return on assets (EBIT) −24.0% · Operating margin −8.1% · Revenue (TTM) 59.0M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −66%, IDLDX screens richer than that median.
Fair Value models
Bearkr 0.0800Fair Value kr 0.1200Bullkr 0.1500
Price kr 0.3500 · Upside -65.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−7.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.9%
’10
’15
’17
’18
’19
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−28,633.3% (2020) → −20.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Neovici Holding AB (publ) with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 127 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−65.7% · Bottom 25%
Profitability
Return on assets−1.8% · Below median
Net margin (12 months)−7.5% · Bottom 25%
Operating margin (12 months)−8.1% · Bottom 25%
Growth and dividend
Revenue growth43.5% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B0.05× · Cheapest 25%
P/S (12 months)0.14× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 22
PAST (return on equity)0· sector 13
HEALTH (low debt)0· sector 93
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Neovici Holding AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/IDLDX
Frequently asked questions
Is Neovici Holding AB (publ) (IDLDX) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 0.1200 versus a price of kr 0.3500, about −66% upside (overvalued).
What is the fair value of IDLDX?
Our model-based fair value for Neovici Holding AB (publ) is kr 0.1200 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 0.3500.
What is the quality score of IDLDX?
Neovici Holding AB (publ) has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neovici Holding AB (publ) (IDLDX)?
Our model-based price target is the fair value of kr 0.1200 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario kr 0.0800, optimistic scenario kr 0.1500. It is a calculation from audited fundamentals, not an analyst target.
What is the Neovici Holding AB (publ) stock forecast for 2026?
Our models put fair value at kr 0.1200, about −66% upside versus a price of kr 0.3500 (overvalued). Cautious scenario kr 0.0800, optimistic scenario kr 0.1500. The calculation is refreshed regularly with new filings.
What is the revenue of Neovici Holding AB (publ) (IDLDX)?
Neovici Holding AB (publ) reported trailing-twelve-month revenue of about 59.0M SEK (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Neovici Holding AB (publ) (IDLDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neovici Holding AB (publ) it is kr 0.1200 per share (as of Oct 3, 2026), against a price of kr 0.3500. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Neovici Holding AB (publ) stock overvalued or undervalued in 2026?
As of Oct 3, 2026, IDLDX trades above its calculated fair value: price kr 0.3500, fair value kr 0.1200, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IDLDX?
No. The price is what the market pays today (kr 0.3500); the fair value is what the company's own numbers justify (kr 0.1200). For Neovici Holding AB (publ) the two are kr 0.2300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neovici Holding AB (publ) worth?
The market values Neovici Holding AB (publ) at about 80.6M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 0.3500; our models calculate a fair value of kr 0.1200 per share.
What do the bullish and bearish scenarios say about IDLDX?
Our models span a range for Neovici Holding AB (publ): cautious scenario kr 0.0800, base kr 0.1200, optimistic kr 0.1500 per share (as of Oct 3, 2026, price kr 0.3500). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neovici Holding AB (publ) (IDLDX)?
Balance-sheet figures for Neovici Holding AB (publ) (as of Oct 3, 2026): return on equity −3.6%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is IDLDX from its 52-week high?
Neovici Holding AB (publ) trades at kr 0.3500, about 33% below its 52-week high of kr 0.5220 and 35% above the low of kr 0.2590 (as of Oct 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1200 is for.
Which stocks are comparable to Neovici Holding AB (publ)?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neovici Holding AB (publ) stock attractive at the current price?
The data as of Oct 3, 2026: price kr 0.3500, calculated fair value kr 0.1200 (−66%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IDLDX calculated?
We run Neovici Holding AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Neovici Holding AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neovici Holding AB (publ) (IDLDX)?
The closing price on Oct 13, 2026 was kr 0.3500. Our model-based fair value is kr 0.1200, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neovici Holding AB (publ) right now?
The price sits above even our optimistic bull case (kr 0.1500). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 0.0800 to kr 0.1500) leaves room in how you read the outcome.
Key figures of Neovici Holding AB (publ)
How large is the market capitalisation of Neovici Holding AB (publ) (IDLDX)?
The market capitalisation of Neovici Holding AB (publ) is 80.6M SEK (≈ $8.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neovici Holding AB (publ) (IDLDX)?
The price-to-sales ratio of Neovici Holding AB (publ) is 1.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neovici Holding AB (publ) (IDLDX)?
Earnings per share at Neovici Holding AB (publ) are kr −0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neovici Holding AB (publ) (IDLDX)?
The net margin of Neovici Holding AB (publ) is −22.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neovici Holding AB (publ) (IDLDX)?
The return on equity (ROE) of Neovici Holding AB (publ) is −3.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neovici Holding AB (publ) (IDLDX)?
On an EBIT basis the return on assets of Neovici Holding AB (publ) is −24.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neovici Holding AB (publ) (IDLDX)?
The operating margin of Neovici Holding AB (publ) is −8.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neovici Holding AB (publ) (IDLDX)?
Revenue at Neovici Holding AB (publ) is growing +43.5% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Neovici Holding AB (publ) (IDLDX) generate?
The free cash flow of Neovici Holding AB (publ) is −9.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Neovici Holding AB (publ) (IDLDX) hold?
Neovici Holding AB (publ) holds more cash than debt, 23.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Neovici Holding AB (publ) in the live analysis
One click puts Neovici Holding AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
